AR127619A1 - FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc - Google Patents
FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-FcInfo
- Publication number
- AR127619A1 AR127619A1 ARP220103074A ARP220103074A AR127619A1 AR 127619 A1 AR127619 A1 AR 127619A1 AR P220103074 A ARP220103074 A AR P220103074A AR P220103074 A ARP220103074 A AR P220103074A AR 127619 A1 AR127619 A1 AR 127619A1
- Authority
- AR
- Argentina
- Prior art keywords
- insulin
- fusions
- phenol
- formulations
- unacceptable loss
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- 230000004927 fusion Effects 0.000 abstract 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 abstract 1
- 239000006096 absorbing agent Substances 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 229960005323 phenoxyethanol Drugs 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163279390P | 2021-11-15 | 2021-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127619A1 true AR127619A1 (es) | 2024-02-14 |
Family
ID=84537390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103074A AR127619A1 (es) | 2021-11-15 | 2022-11-09 | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20250000950A1 (https=) |
| EP (1) | EP4433024A1 (https=) |
| JP (1) | JP2024543457A (https=) |
| KR (1) | KR20240082407A (https=) |
| CN (1) | CN118302152A (https=) |
| AR (1) | AR127619A1 (https=) |
| AU (1) | AU2022386352B2 (https=) |
| CA (1) | CA3238180A1 (https=) |
| CL (1) | CL2024001415A1 (https=) |
| CO (1) | CO2024006121A2 (https=) |
| CR (1) | CR20240202A (https=) |
| DO (1) | DOP2024000084A (https=) |
| EC (1) | ECSP24036789A (https=) |
| IL (1) | IL312623A (https=) |
| JO (1) | JOP20240108A1 (https=) |
| MX (1) | MX2024005879A (https=) |
| PE (1) | PE20241354A1 (https=) |
| TW (1) | TWI871539B (https=) |
| WO (1) | WO2023086980A1 (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097584B2 (en) * | 2005-05-25 | 2012-01-17 | Novo Nordisk A/S | Stabilized formulations of insulin that comprise ethylenediamine |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| US20130011378A1 (en) * | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| AR105616A1 (es) * | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−Ｆｃコンジュゲート |
| KR20210029210A (ko) | 2018-06-29 | 2021-03-15 | 악스톤 바이오사이언시스 코퍼레이션 | 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| WO2020074544A1 (en) | 2018-10-10 | 2020-04-16 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates and their medical use |
| US20220354782A1 (en) * | 2019-09-17 | 2022-11-10 | Cass Pharmaceuticals, Inc. | Subcutaneously injectable insulin and glucagon formulations and methods of administration |
| WO2021119607A1 (en) * | 2019-12-13 | 2021-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | Stable monomeric insulin formulations enabled by supramolecular pegylation of insulin analogues |
| KR20250142943A (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
-
2022
- 2022-11-09 TW TW111142719A patent/TWI871539B/zh active
- 2022-11-09 AR ARP220103074A patent/AR127619A1/es unknown
- 2022-11-14 PE PE2024001075A patent/PE20241354A1/es unknown
- 2022-11-14 CA CA3238180A patent/CA3238180A1/en active Pending
- 2022-11-14 US US18/709,721 patent/US20250000950A1/en active Pending
- 2022-11-14 IL IL312623A patent/IL312623A/en unknown
- 2022-11-14 CN CN202280075570.XA patent/CN118302152A/zh active Pending
- 2022-11-14 JP JP2024527771A patent/JP2024543457A/ja active Pending
- 2022-11-14 CR CR20240202A patent/CR20240202A/es unknown
- 2022-11-14 KR KR1020247015596A patent/KR20240082407A/ko active Pending
- 2022-11-14 EP EP22826289.5A patent/EP4433024A1/en active Pending
- 2022-11-14 AU AU2022386352A patent/AU2022386352B2/en active Active
- 2022-11-14 WO PCT/US2022/079791 patent/WO2023086980A1/en not_active Ceased
- 2022-11-14 MX MX2024005879A patent/MX2024005879A/es unknown
-
2024
- 2024-05-10 CL CL2024001415A patent/CL2024001415A1/es unknown
- 2024-05-13 DO DO2024000084A patent/DOP2024000084A/es unknown
- 2024-05-14 JO JOJO/P/2024/0108A patent/JOP20240108A1/ar unknown
- 2024-05-15 EC ECSENADI202436789A patent/ECSP24036789A/es unknown
- 2024-05-15 CO CONC2024/0006121A patent/CO2024006121A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202339790A (zh) | 2023-10-16 |
| JOP20240108A1 (ar) | 2024-05-14 |
| KR20240082407A (ko) | 2024-06-10 |
| ECSP24036789A (es) | 2024-06-28 |
| PE20241354A1 (es) | 2024-07-03 |
| MX2024005879A (es) | 2024-05-29 |
| CR20240202A (es) | 2024-06-11 |
| CL2024001415A1 (es) | 2024-10-18 |
| CN118302152A (zh) | 2024-07-05 |
| DOP2024000084A (es) | 2024-06-16 |
| EP4433024A1 (en) | 2024-09-25 |
| AU2022386352A1 (en) | 2024-05-09 |
| IL312623A (en) | 2024-07-01 |
| JP2024543457A (ja) | 2024-11-21 |
| US20250000950A1 (en) | 2025-01-02 |
| WO2023086980A1 (en) | 2023-05-19 |
| CO2024006121A2 (es) | 2024-06-27 |
| AU2022386352B2 (en) | 2025-12-18 |
| TWI871539B (zh) | 2025-02-01 |
| CA3238180A1 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133768A2 (es) | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas | |
| CO2018008829A2 (es) | Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos | |
| AR091902A1 (es) | Formulacion liquida de un conjugado de insulina de accion prolongada | |
| AR112480A1 (es) | Composiciones de glp-1 y sus usos | |
| AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| ECSP12011722A (es) | Formulaciones farmacéuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
| CO7151487A2 (es) | Formulación de anticuerpos | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| PE20141185A1 (es) | Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas | |
| CL2019003025A1 (es) | Concentrados espumantes agrícolas que contienen una amida lineal. (divisional solicitud 201603221) | |
| MX2015008528A (es) | Formulaciones para conservacion de organos y tejidos con estabilidad y vida util aumentadas. | |
| PE20230112A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria | |
| AR094874A1 (es) | Formulaciones para el tratamiento de semillas | |
| AR061830A1 (es) | Formulacion liquida no acuosa altamente eficaz de piretroides | |
| MX389554B (es) | Formulaciones antihelminticas veterinarias estables. | |
| CL2024001961A1 (es) | Proteína de fusión permeable a la barrera hematoencefálica y usos de ésta | |
| AR127619A1 (es) | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc | |
| CO2017003787A2 (es) | Limoneno: formulación y uso insecticida | |
| AR061802A1 (es) | Composicion que tiene una actividad que previene la germinacion, procedimientos para obtener dichas composiciones y uso de las mismas | |
| CL2022002472A1 (es) | Formulaciones líquidas de análogos de glucagón | |
| PE20200017A1 (es) | Composiciones de insulina de rapida accion | |
| AR107276A1 (es) | Una formulación líquida de conjugado de hormona del crecimiento humana de acción prolongada | |
| MX2024004656A (es) | Formulaciones acuosas de un anticuerpo anti-cd22 y usos de las mismas. | |
| AR052882A1 (es) | Composicion antihelmintica |